News

News

University of California, San Francisco and Phase Holographic Imaging establish Center of Excellence

University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have agreed to expand their on-going collaboration and establish a regional Holographic Imaging Cytometry Center of Excellence, located at the UCSF Helen Diller Family Comprehensive Cancer Center.

Read more

Novel HoloMonitor method identifies tumor creating cancer cells

Using HoloMonitor®, researchers at Harvard Medical School and Boston Children’s Hospital have developed a novel non-invasive method for distinguishing between active and dormant cancer cells.

Read more

New CEO commentary: “The scientific role of commercialization”

On PHI’s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco “The evolution of Phase Holographic Imaging from a research idea to publicly traded company”, see CEO commentary The scientific role of commercialization, published February 18, 2018.

Read more

PHI and Germany’s federal institute for materials research pursue joint patent application

Phase Holographic Imaging (PHI) and Germany’s federal institute for materials research (BAM) has agreed to jointly enter the national phase of international patent application “Molecularly Imprinted Polymers” in Europe, USA, China and Japan. An international patent application is a preliminary review prior to national applications. Patents are only granted nationally.

Read more

PHI Launches Wound Healing Assay

HoloMonitor® Wound Healing Assay: The assay meets the unmet market demand of both quantifying cell movement automatically and in great detail. Wound healing assays are one of the most used laboratory methods to study cell movement. Conventional wound healing assays are either manual or just measure the collective movement of a cell population.

Read more

Option Exercised IV

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.

Read more

Options Exercised III

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company

Read more

Leading Australian Research Institute Purchases HoloMonitor

A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation.

Read more

Options Exercised II

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.

Read more

Options Exercised I

Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget.

Read more